Walter TO

Language: Spanish
References: 10
Page: s29-36
PDF size: 245.26 Kb.

REFERENCES

1. Makarovska-Bojadzieva T, Blagoevska M, Kolevski P, Kostovska S: Optimal blood grouping and antibody screening for safe transfusion. Prilozi. 2009; 1: 119-128.

2. Marcucci C, Madjdpour C, Spahn DR. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull. 2004; 70: 15-28.

3. Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006; 46 (2): 250-256.

4. Higgins JM, Sloan SR. Stochastic modelling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood. 2008; 112 (6): 2546-2553.

5. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briet E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion. 2007; 47 (11): 2066-2071.

6. Cortés Buelvas A. Rev. Arg. Trsnf. Vol L Nº1 2024 pp 39-51

7. Spinelli SL, Otheguy LE, Larguia MA. Postnatal use of high-dose intravenous immunoglobulin therapy in Rhesus hemolytic disease treatment. J Perinat Med. 2001; 29 (Suppl. 1): 683.

8. Kilby MD, Bussel JB, Moise KJ Jr. The contemporary management of haemolytic disease of the fetus and newborn. Vox Sang. 2025; 120 (7): 644-652. doi: 10.1111/vox.70027.

9. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. Br J Haematol. 1986; 63 (2): 241-245.

10. Kohan AI, Reybaud JF, Salamone HJ, Rey JA, Rey CE, Villaravid N et al. Management of a severe transfusional problem in a patient with alloantibody to Kpb (K4). Vox Sang. 1990; 59 (4): 216-217.